Researchers at MIT reported a next‑generation lipid nanoparticle (LNP) formulation that delivered an influenza mRNA vaccine at roughly 1/100th the dose required by current FDA‑approved LNP materials in mice while achieving comparable immune responses. The work, published in Nature Nanotechnology, centers on a degradable cyclic amino alcohol ionizable lipid (AMG1541) optimized for endosomal escape and biodegradability. The team used combinatorial synthesis and in vivo screening to select ionizable lipids that enhance delivery potency and reduce toxicity, demonstrating robust luciferase reporter expression and protective immune responses at drastically lower mRNA loads. Authors argue the approach could lower manufacturing costs and adverse‑event risk for future mRNA vaccines and therapeutics. Translational steps will require safety and manufacturability assessments, but the study signals a potential pathway to more economical, lower‑reactogenicity mRNA products if similar results translate to humans.